
Japan Lifeline Co., Ltd.
7575.TJPXHealthcareMedical - Devices
Latest quote
¥1,569
−¥7.00 · -0.44%
7575.T company overview
Regular session · JST · Market data may be delayed.
Company profile
Company websiteJapan Lifeline Co., Ltd. is a medical technology firm based in Japan that specializes in cardiovascular healthcare devices. Its operations encompass research, manufacturing, global procurement, and sales of these specialized medical instruments within the country. The company's diverse product range includes solutions for cardiac rhythm management, such as pacemakers, implantable cardioverter defibrillators (including subcutaneous models), cardiac resynchronization therapy defibrillators and pacemakers, automated external defibrillators, and cardiopulmonary resuscitation support tools. For electrophysiology and ablation procedures, Japan Lifeline offers various electrophysiological and ablation catheters (like irrigated tip versions), endoscopic balloon ablation systems, esophageal temperature monitors, internal atrial cardioversion systems, and radio-frequency transseptal needles. Furthermore, its portfolio extends to cardiovascular and endografting products, including vascular, open, and abdominal stent-grafts. In the transvascular intervention segment, the company provides PTCA and PTA guide wires, PTCA balloon catheters, radiofrequency wires, and devices for closing atrial septal defects. Complementing these, its gastrointestinal intervention solutions encompass radiofrequency ablation systems, self-expandable colonic stents, and endoscopic guidewires. Established in 1981, Japan Lifeline Co., Ltd. maintains its headquarters in Tokyo, Japan.
- Industry
- Medical - Devices
- Sector
- Healthcare
- Headquarters
- JP
- CEO
- Keisuke Suzuki
- Listed since
- Jan 4, 2000
- Employees
- 1,304
Market position
- Volume
- 89.2K
- 0.46× average
- Average volume
- 192.49K
- Average daily volume
- Market cap
- 110.07B JPY
- Beta
- 0.36
- Market reference 1
Financials
Financial snapshot
Latest / TTMValuation & yield
- P/E (TTM)
- 11.76×
- P/B (TTM)
- 1.71×
- P/S (TTM)
- 1.82×
- Dividend yield
- 3.44%
Profitability & efficiency
- Gross margin
- 57.69%
- Operating margin
- 19.16%
- Net margin
- 15.47%
Financial health
- Debt / equity
- 0.06×
- Altman Z-score
- 8.36
- Piotroski F-score
- 3 of 9
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (JPY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 59.19B JPY | 56.61B JPY | 51.38B JPY | 51.75B JPY | 51.47B JPY |
| Cost of goods sold | 24.71B JPY | 23.51B JPY | 21.01B JPY | 22.77B JPY | 23.61B JPY |
| Gross profit | 34.48B JPY | 33.1B JPY | 30.38B JPY | 28.99B JPY | 27.86B JPY |
| Research and development | 3.1B JPY | 2.85B JPY | 2.37B JPY | 2.32B JPY | 2.16B JPY |
| Selling, general, and administrative | 18.79B JPY | 17.73B JPY | 16.97B JPY | 15.83B JPY | 15.74B JPY |
| Operating expenses | 21.9B JPY | 20.58B JPY | 19.34B JPY | 18.15B JPY | 17.9B JPY |
| Interest income | 165M JPY | 196M JPY | 156M JPY | 105M JPY | 63M JPY |
| Interest expense | 34M JPY | 36M JPY | 26M JPY | 34M JPY | 76M JPY |
| Depreciation and amortization | 1.97B JPY | 2.1B JPY | 1.79B JPY | 1.88B JPY | 1.93B JPY |
| Operating income | 12.59B JPY | 12.52B JPY | 11.04B JPY | 10.84B JPY | 9.96B JPY |
| Net income | 9.35B JPY | 9.32B JPY | 7.52B JPY | 6.89B JPY | 7.48B JPY |
Company facts updated Aug 24, 2026.
Earnings
- Latest EPS result
- 32.93
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
7575.T peers
Continue in GoAI
Research 7575.Tresearch.disclaimer





